AntriaBio licenses portfolio of enzymes to treat vision loss in adults

LOUISVILLE — AntriaBio Inc. (OTC: ANTB) is licensing from ActiveSite Pharmaceuticals.

AntriaBio is licensing ActiveSite’s oral plasma kallikrein inhibitor portfolio, which will be used in human and animal health, according to a news release.

The portfolio will be used for targeting the treatment of diabetic macular edema and other plasma kallikrein-mediated diseases.  Diabetic macular edema is the primary cause of vision loss in working-age adults globally. About 750,000 people in the United States and another six to nine million worldwide have diabetic macular edema. It results from the breakdown of the flood-retinal barrier and an increase in retinal vascular permeability, or RVP. Plasma kallikrein is an enzyme, and kallikreins are capable of cleaving peptide bonds in proteins. Plasma kallikrein has been shown to mediate RVP.

Under the agreement, AntriaBio will have worldwide rights to the portfolio and will take over global development and commercial responsibilities. ActiveSite will receive an upfront payment and will be eligible for future payments, including royalties.